During the recent session, Nektar Therapeutics (NASDAQ:NKTR)’s traded shares were 0.84 million, with the beta value of the company hitting 0.56. At the last check today, the stock’s price was $1.08, reflecting an intraday gain of 6.93% or $0.07. The 52-week high for the NKTR share is $1.93, that puts it down -78.7 from that peak though still a striking 61.11% gain since the share price plummeted to a 52-week low of $0.42. The company’s market capitalization is $199.21M, and the average intraday trading volume over the past 10 days was 1.68 million shares, and the average trade volume was 1.30 million shares over the past three months.
Nektar Therapeutics (NKTR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.71. NKTR has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.18.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nektar Therapeutics (NASDAQ:NKTR) trade information
Nektar Therapeutics (NKTR) registered a 6.93% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.93% in intraday trading to $1.08, hitting a weekly high. The stock’s 5-day price performance is 0.93%, and it has moved by -20.00% in 30 days. Based on these gigs, the overall price performance for the year is 118.62%. The short interest in Nektar Therapeutics (NASDAQ:NKTR) is 5.23 million shares and it means that shorts have 3.91 day(s) to cover.
The consensus price target of analysts on Wall Street is $18.5, which implies an increase of 94.16% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $24 respectively. As a result, NKTR is trading at a discount of -2122.22% off the target high and -455.56% off the low.
Nektar Therapeutics (NKTR) estimates and forecasts
Statistics show that Nektar Therapeutics has outperformed its competitors in share price, compared to the industry in which it operates. Nektar Therapeutics (NKTR) shares have gone down -34.15% during the last six months, with a year-to-date growth rate more than the industry average at 47.59% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 18.18% this quarter and then drop -19.57% in the quarter after that. In the rating firms’ projections, revenue will increase 10.68% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 31.39M as predicted by 6 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 25.7M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 23.89M and 21.64M respectively. In this case, analysts expect current quarter sales to grow by 31.42% and then jump by 18.77% in the coming quarter.
While earnings are projected to return 49.34% in 2024, the next five years will return -7.30% per annum.
NKTR Dividends
Nektar Therapeutics is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Nektar Therapeutics insiders own 1.04% of total outstanding shares while institutional holders control 76.64%, with the float percentage being 77.45%. DEEP TRACK CAPITAL, LP is the largest shareholder of the company, while 176.0 institutions own stock in it. As of 2024-06-30, the company held over 17.88 million shares (or 9.1789% of all shares), a total value of $22.17 million in shares.
The next largest institutional holding, with 15.16 million shares, is of BLACKROCK INC.’s that is approximately 7.7823% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $18.79 million.
Also, the Mutual Funds coming in first place with the largest holdings of Nektar Therapeutics (NKTR) shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund. Data provided on Jun 30, 2024 indicates that Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund owns about 7.53 shares. This amounts to just over 4.08 percent of the company’s overall shares, with a $8.13 million market value. The same data shows that the other fund manager holds slightly less at 5.72, or about 3.10% of the stock, which is worth about $6.18 million.
